The rapidly advancing field of biodefense benefits many other, critical public health concerns.
Identifieur interne : 002614 ( PubMed/Curation ); précédent : 002613; suivant : 002615The rapidly advancing field of biodefense benefits many other, critical public health concerns.
Auteurs : James C. Burnett [États-Unis] ; Rekha G. Panchal ; M Javad Aman ; Sina BavariSource :
- Discovery medicine [ 1944-7930 ] ; 2005.
Abstract
Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared?
PubMed: 20704875
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002614
Links to Exploration step
pubmed:20704875Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The rapidly advancing field of biodefense benefits many other, critical public health concerns.</title><author><name sortKey="Burnett, James C" sort="Burnett, James C" uniqKey="Burnett J" first="James C" last="Burnett">James C. Burnett</name><affiliation wicri:level="1"><nlm:affiliation>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702</wicri:regionArea></affiliation></author><author><name sortKey="Panchal, Rekha G" sort="Panchal, Rekha G" uniqKey="Panchal R" first="Rekha G" last="Panchal">Rekha G. Panchal</name></author><author><name sortKey="Aman, M Javad" sort="Aman, M Javad" uniqKey="Aman M" first="M Javad" last="Aman">M Javad Aman</name></author><author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:20704875</idno><idno type="pmid">20704875</idno><idno type="wicri:Area/PubMed/Corpus">002614</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002614</idno><idno type="wicri:Area/PubMed/Curation">002614</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002614</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The rapidly advancing field of biodefense benefits many other, critical public health concerns.</title><author><name sortKey="Burnett, James C" sort="Burnett, James C" uniqKey="Burnett J" first="James C" last="Burnett">James C. Burnett</name><affiliation wicri:level="1"><nlm:affiliation>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702</wicri:regionArea></affiliation></author><author><name sortKey="Panchal, Rekha G" sort="Panchal, Rekha G" uniqKey="Panchal R" first="Rekha G" last="Panchal">Rekha G. Panchal</name></author><author><name sortKey="Aman, M Javad" sort="Aman, M Javad" uniqKey="Aman M" first="M Javad" last="Aman">M Javad Aman</name></author><author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name></author></analytic><series><title level="j">Discovery medicine</title><idno type="eISSN">1944-7930</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared?</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">20704875</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7930</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>28</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Discovery medicine</Title><ISOAbbreviation>Discov Med</ISOAbbreviation></Journal><ArticleTitle>The rapidly advancing field of biodefense benefits many other, critical public health concerns.</ArticleTitle><Pagination><MedlinePgn>371-7</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared?</AbstractText><AbstractText Label="ANSWER" NlmCategory="CONCLUSIONS">in a very short period of time the scientific community has responded with a massive and productive effort. Driving the research advances described in this review: 1) a vastly improved understanding of the biological mechanisms and machinery used by biothreat agents; 2) state-of-the-art high-throughput screening technologies; and 3) more efficient, standardized methods and improved protocols for detecting, identifying, and diagnosing biowarfare agents. Furthermore, as with all good science, many recent biodefense research discoveries/advances have also directly facilitated our understanding and ability to treat other diseases, including antibiotic resistant bacteria and viruses (such as HIV and SARS).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>James C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panchal</LastName><ForeName>Rekha G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Aman</LastName><ForeName>M Javad</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Bavari</LastName><ForeName>Sina</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Discov Med</MedlineTA><NlmUniqueID>101250006</NlmUniqueID><ISSNLinking>1539-6509</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20704875</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002614 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002614 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20704875
|texte= The rapidly advancing field of biodefense benefits many other, critical public health concerns.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20704875" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |